Conclusion of the article:

The Lorrca with Oxygenscan can fully characterize RBC deformability under a range of oxygen concentrations. Key measurements – PoS, EImin, and EImax – were different between genotypes, and changed significantly with standard of care SCD treatments. We therefore conclude that these are useful biomarkers of clinical severity and treatment response, and may be essential in monitoring novel SCD treatments as part of a clinical trial.


The Oxygenscan: a rapid and reproducible source of clinically relevant biomarkers in for patients with sickle cell disease

Celeste K. Kanne(3), Minke A.E. Rab(1,2), Brigitte A. van Oirschot(1), Jennifer Bos(1), Maite E. Houwing(4), Marjon H. Cnossen(4) Roger E.G. Schutgens(2), Gerard Pasterkamp(1), Richard van Wijk(1), Eduard J. van Beers(2) and Vivien A. Sheehan(3)

(1) Laboratory of Clinical Chemistry & Haematology, University Medical Center Utrecht,

(2) Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands

(3) Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston Texas, USA

(4) Department of Pediatric Hematology, Erasmus Medical Center, Rotterdam, The Netherlands

Article will be presented at:

13th Annual Sickle Cell Disease Research and Educational Symposium